Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma/paraganglioma
Endocrine-Related Cancer · 2023
DOI: 10.1530/erc-22-0236 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine-Related Cancer, 2023. Verfasst von Camilo Jimenez und 7 weiteren Autor:innen. Beteiligte Einrichtung: University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Pheochromocytoma, Paraganglioma, Adrenal Gland Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
The objective of this study is to present the complete biomarker response dataset from a pivotal trial evaluating the efficacy and safety of high-specific-activity I-131 meta-iodobenzylguanidine in patients with advanced pheochromocytoma or paraganglioma. Biomarker status was assessed and post-treatment responses were analyzed for catecholamines, metanephrines, and serum chromogranin A. Complete biomarker response (normalization) or partial response, defined as at least 50% reduction from baseline if above the normal range, was evaluated at specified time points over a 12-month period. These results were correlated with two other study objectives: blood pressure control and objective tumor response as per RECIST 1.0. In this open-label, single-arm study, 68 patients received at least one therapeutic dose (~18.5 GBq (~500 mCi)) of high-specific-activity I-131 meta-iodobenzylguanidine. Of the patients, 79% and 72% had tumors associated with elevated total plasma free metanephrines and serum chromogranin A levels, respectively. Best overall biomarker responses (complete or partial response) for total plasma free metanephrines and chromogranin A were observed in 69% (37/54) and 80% (39/49) of patients, respectively. The best response for individual biomarkers was observed 6–12 months following the first administration of high-specific-activity I-131 meta-iodobenzylguanidine. Biochemical tumor marker response was significantly associated with both reduction in antihypertensive medication use (correlation coefficient 0.35; P = 0.006) as well as objective tumor response (correlation coefficient 0.36; P = 0.007). Treatment with high-specific-activity I-131 meta-iodobenzylguanidine resulted in long-lasting biomarker responses in patients with advanced pheochromocytoma or paraganglioma that correlated with blood pressure control and objective response rate. ClinicalTrials.gov number: NCT00874614.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
- Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.
- University of Iowa, Iowa City, Iowa, USA.
- Johns Hopkins Medicine, Baltimore, Maryland, USA.
- Progenics Pharmaceuticals, Inc., a Lantheus Company, North Billerica, Massachusetts, USA.
ORCID-Profile: Camilo Jimenez, Vincent A DiPippo
Förderung
- NCI NIH HHS
Zitieren
APA
Jimenez, C., Chin, B. B., Noto, R. B., Dillon, J. S., Solnes, L., Stambler, N., DiPippo, V. A., & Pryma, D. A. (2023). Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma/paraganglioma. Endocrine-Related Cancer. https://doi.org/10.1530/erc-22-0236
Vancouver
Jimenez C, Chin BB, Noto RB, Dillon JS, Solnes L, Stambler N, et al. Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma/paraganglioma. Endocrine-Related Cancer. 2023. doi:10.1530/erc-22-0236
BibTeX
@article{Jimenez2023,
author = {Jimenez, Camilo and Chin, Bennett B and Noto, Richard B and Dillon, Joseph S and Solnes, Lilja and Stambler, Nancy and DiPippo, Vincent A and Pryma, Daniel A},
title = {Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma/paraganglioma},
journal = {Endocrine-Related Cancer},
year = {2023},
doi = {10.1530/erc-22-0236}
}
EUVIMED